Community transmission of SARS-CoV-2 lineage with novel mutations in Florida

New variants of concern (VOCs) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are continually emerging and spreading on a global scale. Therefore, there is a need for increased SARS-CoV-2 genomic surveillance for different variants at the local, national, and international levels.

A new study describes the introduction and spread of a SARS-CoV-2 lineage, A.2.5 in Florida using samples from the Florida Department of Health (FDOH) Bureau of Public Health Laboratories (BPHL). BPHL performs whole-genome sequencing for surveillance of SARS-CoV-2 isolates in Florida from clinical samples collected from county health departments and hospitals throughout the state.

Study: Introduction and community transmission of SARS-CoV-2 lineage A.2.5 in Florida with novel spike INDELS. Image Credit: Alexander Lukatskiy/Shutterstock

Study: Introduction and community transmission of SARS-CoV-2 lineage A.2.5 in Florida with novel spike INDELS. Image Credit: Alexander Lukatskiy/Shutterstock

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

A preprint version of the study, which is yet to undergo peer review, is available on the medRxiv* server.

Genomic surveillance

SARS-CoV-2 surveillance involves the identification and tracking of lineages that contain mutations and/or insertions/deletions (INDELS) within the SARS-CoV-2 spike protein. It is achieved by tiled-amplicon whole-genome sequencing (WGS) or targeted enrichment WGS.

The Centers for Disease Control and Prevention (CDC) has published a United States (U.S.) government interagency variant classification list. According to this, the variants are classified as - variant of interest (VOI), variant of concern (VOC) and variant of high consequence (VOHC). As of June 4, 2021, the U.S. majorly has VOCs and VOIs. Florida had more than 80% of VOCs among all lineages.

BPHL has sequenced coronavirus disease 2019 (COVID-19)-positive samples collected from patients throughout the state since March 4, 2020. BPHL actively surveils variants of public health interest in Florida. It monitors changes in lineage frequencies within the state and the emergence of novel spike protein mutations which may warrant further research.

Lineage A.2.4

In January 2021, BPHL detected the lineage A.2.4 among patients in an outbreak at a south Florida healthcare facility. Shortly, additional A.2.4 cases were detected during routine surveillance from patients geographically dispersed across the state. The A.2.4 lineage first emerged in Panama. It comprised a distinct clade that contained mainly U.S. samples.

This separate clade was then reclassified as lineage A.2.5, a Central American/U.S. lineage. SARS-CoV-2 A.2.5 isolates from Florida were first detected among a healthcare facility outbreak involving both patients and staff. The A.2.5 isolates contained several spike mutations which warranted further investigation. The spike protein of A.2.5 lineage harbors a CDC-designated substitution of therapeutic concern (L452R), the independent emergence of substitution D614G in an A lineage, and two novel spike INDELs - LGV141-143del and ins215AGY. These were never detected in Florida nor reported in any of the SARS-CoV-2 studies. Moreover, the implications of these mutations on the immune system are unknown.

Lineage A.2.5

As of March 29, 2021, the global A.2.5 lineage had 220 isolates with complete genomes from 13 countries. The earliest A.2.5 isolate was collected in Ecuador on December 1, 2020. Of these 220 isolates, 33 were from Florida. The first clinical sample from Florida was collected on January 16, 2021. The spike protein gene of this lineage has the most common spike protein mutations including S:D614G (98.64%), S:L452R (97.27%), S:G142- (97.27%), S:V143- (97.27%), S:L141- (95.45%), S:D215A (76.82%), and S:ins215AGY (76.82%). Samples from Florida had similar mutations frequencies S:D614G (96.97%), S:L452R (96.97%), S:G142- (100%), S:V143- (100%), S:L141- (100%), S:D215A (87.88%), and S:ins215AGY (87.88%).

A time-scaled maximum clade credibility phylogeny indicated multiple introductions of this lineage. There were at least eight separate introductions of A.2.5 in Florida. The time of introduction of a monophyletic Florida clade was determined to be December 2020.

The three-dimensional structure of the mutant spike protein was modeled using computational methods to locate the INDELS within the protein structure. Within the primary Florida clade, all samples had spike L141del, G142del, V143del, D215A, ins215AGY, L452R, and D614G. However, three out of 17 isolates had missing and low coverage at spike 215. The deletions of Spike 141- 143 and the insertion at 215 were most notable. The spike protein INDELS reside in the N-terminal domain. This is a region associated with antibody neutralization.

Implications

Several variants have mutations in the N-terminal domain. This region is under selective pressure for the emerging variants to escape neutralization by antibodies. Additional mutations can cause increased transmissibility. The A.2.5 lineage does not appear to have increased transmissibility due to the low frequency of the lineage in the U.S. and globally. However, A.2.5 and its emerging sublineages should continue to be monitored as novel mutations could arise that may increase transmissibility.

Continued genomic surveillance and contact tracing are critical for informing a public health response to reduce or eliminate the transmission of SARS-CoV-2 variants.

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Shital Sarah Ahaley

Written by

Dr. Shital Sarah Ahaley

Dr. Shital Sarah Ahaley is a medical writer. She completed her Bachelor's and Master's degree in Microbiology at the University of Pune. She then completed her Ph.D. at the Indian Institute of Science, Bengaluru where she studied muscle development and muscle diseases. After her Ph.D., she worked at the Indian Institute of Science, Education, and Research, Pune as a post-doctoral fellow. She then acquired and executed an independent grant from the DBT-Wellcome Trust India Alliance as an Early Career Fellow. Her work focused on RNA binding proteins and Hedgehog signaling.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sarah Ahaley, Shital. (2021, December 07). Community transmission of SARS-CoV-2 lineage with novel mutations in Florida. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20211207/Community-transmission-of-SARS-CoV-2-lineage-with-novel-mutations-in-Florida.aspx.

  • MLA

    Sarah Ahaley, Shital. "Community transmission of SARS-CoV-2 lineage with novel mutations in Florida". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20211207/Community-transmission-of-SARS-CoV-2-lineage-with-novel-mutations-in-Florida.aspx>.

  • Chicago

    Sarah Ahaley, Shital. "Community transmission of SARS-CoV-2 lineage with novel mutations in Florida". News-Medical. https://www.news-medical.net/news/20211207/Community-transmission-of-SARS-CoV-2-lineage-with-novel-mutations-in-Florida.aspx. (accessed November 21, 2024).

  • Harvard

    Sarah Ahaley, Shital. 2021. Community transmission of SARS-CoV-2 lineage with novel mutations in Florida. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20211207/Community-transmission-of-SARS-CoV-2-lineage-with-novel-mutations-in-Florida.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Futuristic AI-powered virtual lab designs potent SARS-CoV-2 nanobodies